International media coverage of QazVac vaccine
This week, the world’s leading media outlets have devoted attention to Kazakhstan and its domestic coronavirus vaccine. EU Reporter, which is a Brussels-based news platform that provides news on EU affairs, published an article covering the launch of the rollout of QazVac vaccine in Kazakhstan. The development of an inactivated vaccine is a strong indication of the country’s scientific and industrial potential, it reported. The Central Asian country has become one of the few countries in the world that had developed their own COVID-19 vaccines. The article also notes that two million doses of QazVac will be produced by the end of the year.
In its article dedicated to Kazakh homegrown coronavirus vaccine, a British news and media website The Guardian notes that QazVac is a two-shot vaccine that is in third-stage trials. 50,000 doses of the vaccine developed by the Research Institute for Biological Safety Problems have been distributed across the country.
Another well-known foreign media outlet, Indonesian REPUBLIKA.CO.ID, writes that Kazakhstan is one of the five countries in the world that have developed their own COVID-19 vaccine. The country’s Health Minister Alexey Tsoy has already received the first dose of the domestic vaccine.
The Swiss international service SWI swissinfo.ch notes in its article that preclinical trials of the Kazakh vaccine began in May 2020, two months after the outbreak of the coronavirus pandemic. The results of the following studies showed that the vaccine is 96 percent effective. In the future, its production is expected to increase to 500,000- 600,000 doses per month.
Translation by Assem Zhanmukhanova
Editing by Galiya Khassenkhanova